SPTX — Seaport Therapeutics, Inc. Common Stock stock price, charts and financials

QT73Seaport Therapeutics, Inc. Common Stock

Latest market price

21.43

+0.78+3.78%

Overview Short InterestFilings

SPTXQT73Seaport Therapeutics, Inc. Common Stock·NASDAQ

Overview Short InterestFilings

21.43+3.78%

Loading chart...

Signal & projected range

QT Score upgradeHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

OCUL+2.26%$8.59 MESO+2.28%$14.80 AUPH+2.47%$14.93 TYRA+1.53%$32.53 URGN+3.45%$39.92 IOVA+0.93%$4.36 STOK+7.14%$31.67 TSHA+7.27%$6.20

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	31.17%	Shs Outstand	53.53M	Perf Week	7.69%

Market Cap	1.15B	Forward P/E	-	EPS next Y	-2.45	Insider Trans	0.00%	Shs Float	17.51M	Perf Month	10.64%

Enterprise Value	934.16M	PEG	-	EPS next Q	-0.71	Inst Own	-	Short Float	3.70%	Perf Quarter	26.06%

Income	-75.00M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	5.51	Perf Half Y	-

Sales	0.00	P/B	-	EPS next Y	57.70%	ROA	-30.07%	Short Interest	1.98M	Perf YTD	2.05%

Book/sh	-1.74	P/C	5.31	EPS next 5Y	-	ROE	80.91%	52W High	23.00 -6.83%	Perf Year	-

Cash/sh	4.04	P/FCF	-	EPS past 3/5Y	-	ROIC	-36.70%	52W Low	14.85 44.31%	Perf 3Y	-

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	6.81% 8.17%	Perf 5Y	-

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	-	Oper. Margin	0.00%	ATR (14)	1.55	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	17.46	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	56.51	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	17.46	EPS Q/Q	-	SMA20	3.62%	Beta	0.85	Target Price	43.33

Payout	0.00%	Debt/Eq	-	Sales Q/Q	-	SMA50	10.65%	Rel Volume	0.40	Prev Close	20.65

Employees	58	LT Debt/Eq	-0.03	Earnings	Nov 02	SMA200	14.69%	Avg Volume	223.23K	Price	21.43

IPO Date	May 01, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	-93.78% -	Net Debt/EBITDA	0.48	Volume	89,901	Change	3.78%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-04-26	Reiterated	HC Wainwright & Co.	Buy	$50
Jul-15-26	Initiated	H.C	Buy	$50
May-26-26	Initiated	Leerink	Outperform	$35
May-26-26	Initiated	Stifel	Buy	$30
May-26-26	Initiated	JPMorgan	Overweight	$42

Latest News

Aug-03-26

Aug-03-2607:05AM

Seaport Therapeutics Q2 EPS $(1.78) Misses $(0.65) EstimateBenzinga

07:00AM

Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progressbusinesswire.com

Jul-15-26

Jul-15-2606:42AM

HC Wainwright & Co. Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $50Benzinga

Company

Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)		FY 2025 12/31/2025
Total Revenue		0
Cost of Goods Sold Incl. D&A		0
Gross Profit		0
Selling, General and Administrative Excl. Other		21
Research and Development		66
Other Operating Expense		0
Operating Income		-87
Interest Expense		0
Unusual Expense		—
Non-Operating Income (Expense)		13
Net Income Before Taxes		-74
Income Taxes		1
Consolidated Net Income		-75
Net Income From Continuing Operations		-75
Net Income		-75
EPS (Recurring)		-1.94
EPS (Basic, Before Extraordinaries)		-1.94
EPS (Diluted)		-1.94
EBITDA		-86
Other After Tax Adjustments		—
Stock Option Compensation Expense		—
Price To Earnings Ratio		—
Price To Sales Ratio		—
Gross Margin		—
Operating Margin		—
Net Margin		—
Shares Outstanding		39
Market Capitalization		—
Operating Lease Expense		—

Insider Trading Volume

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.